ClinicalTrials.gg
CompletedNCT03140969Updated Oct 15, 2024Results posted

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

A Phase 1/2 interventional study of QR-110 in Leber's Congenital Amaurosis, sponsored by Laboratoires Thea. Completed at 3 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Laboratoires Thea · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States — 4 open to participants now, 6 under way, 2 of them phase 3. Optic Atrophy, Hereditary, Leber · United States.

Enrollment
16th of 19
11 · median 36
Started
2017
the only one that year
Phase 1/2
5 of 23
none open now
Registered
14th of 23
by date
Lead sponsor
3 of 23
Laboratoires Thea

Among the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States, this one is the 16th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 1/2, and was the 14th registered.

Optic Atrophy, Hereditary, Leber

44 studies on the registry are indexed under Optic Atrophy, Hereditary, Leber; 9 are open to participants now.

Browse Optic Atrophy, Hereditary, Leber studies →

Open to participants now

4 of the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Optic Atrophy, Hereditary, Leber studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.

Read the detailed description

The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation. Subjects will receive QR-110 in one eye every 3 months, for a maximum of 4 doses. Up to 3 dose levels of QR-110 will be evaluated.

03

Conditions studied

  • Leber's Congenital Amaurosis

Keywords

  • CEP290
  • p.Cys998X
  • c.2991+1655A>G
  • RNA therapy
  • Antisense oligonucleotide
  • Leber's congenital amaurosis
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ≥ 6 years of age at Screening with a clinical diagnosis of LCA and a molecular diagnosis of homozygosity or compound heterozygosity for the CEP290 p.Cys998X mutation.
  • Best-corrected visual acuity greater than or equal to light perception in both eyes and equal to or worse than LogMAR +1.0 (Snellen notation 20/200) in the worse eye and equal to or worse than LogMAR +0.7 (Snellen notation 20/100) in the contralateral eye.
  • Detectable outer nuclear layer (ONL) in the area of the macula.
  • An electroretinogram (ERG) result consistent with LCA.
  • Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging.

Exclusion criteria

Exclusion Criteria:

  • Syndromic disease.
  • Pregnant or breast-feeding female.
  • Any cardiac disease or defect.
  • One or more coagulation parameters outside of the normal range.
  • Any ocular disease or condition that could compromise treatment safety, visual acuity or interfere with assessment of efficacy and safety.
  • Prior receipt of intraocular surgery or intravitreal injection within 3 months prior to study start or planned intraocular surgery or procedure during the course of the study.
  • Use of any drug or device within 90 days or 5 half-lives of Day 1, whichever is longer, or plans to participate in another study of a drug or device during the PQ-110-001 study period.
  • Any prior receipt of genetic therapy for LCA
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    QR-110

    Administered every 3 months

    Drug: QR-110

Interventions

  • DrugQR-110

    RNA antisense oligonucleotide for intravitreal injection

    Also known as: Sepofarsen

06

What researchers measure

Primary outcomes

  1. Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes

    Time frame: 1 year

Secondary outcomes

  1. Frequency and Severity of Non-ocular Adverse Events

    Time frame: 1 year

  2. Change in Best-corrected Visual Acuity (BCVA)

    Time frame: 1 year

  3. Change in Full-field Stimulus Test (FST)

    Average Red Light Score

    Time frame: 1 year

  4. Change in Full-field Stimulus Test (FST)

    Average Blue Light Score

    Time frame: 1 year

07

Results

Posted Dec 27, 2022

Participant flow

Participant flow — Overall Study
MilestoneQR-110 Low DoseQR-110 Mid DoseQR-110 High Dose
Started650
Completed650
Not completed000

Outcome measures

PrimaryFrequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes
Time frame:
1 year
Reported as:
Count of participants · Participants
Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes
ParticipantsQR-110 Low DoseQR-110 Mid Dose
Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes65
SecondaryFrequency and Severity of Non-ocular Adverse Events
Time frame:
1 year
Reported as:
Count of participants · Participants
Frequency and Severity of Non-ocular Adverse Events
ParticipantsQR-110 Low DoseQR-110 Mid Dose
Frequency and Severity of Non-ocular Adverse Events65
SecondaryChange in Best-corrected Visual Acuity (BCVA)
Time frame:
1 year
Reported as:
Mean · logMAR
Change in Best-corrected Visual Acuity (BCVA)
logMARQR-110 Low DoseQR-110 Mid Dose
Baseline (Absolute Values)2.597 ± 1.27382.990 ± 1.4153
Changes from Baseline - Visit 8 (M3)-0.813 ± 1.0073-0.126 ± 0.2165
Changes from Baseline - Visit 13 (M6)-0.903 ± 1.0189-0.122 ± 0.1801
Changes from Baseline - Visit 17 (M9)-0.923 ± 1.04170.386 ± 0.9610
Changes from Baseline - Visit 21 (M12)-0.927 ± 1.0492-0.106 ± 0.1545
SecondaryChange in Full-field Stimulus Test (FST)

Average Red Light Score

Time frame:
1 year
Reported as:
Mean · log cd/m2
Change in Full-field Stimulus Test (FST)
log cd/m2QR-110 Low DoseQR-110 Mid Dose
Change in Full-field Stimulus Test (FST)-0.7 ± 0.33-1.2 ± 0.82
SecondaryChange in Full-field Stimulus Test (FST)

Average Blue Light Score

Time frame:
1 year
Reported as:
Mean · log cd/m2
Change in Full-field Stimulus Test (FST)
log cd/m2QR-110 Low DoseQR-110 Mid Dose
Change in Full-field Stimulus Test (FST)-0.6 ± 0.76-0.9 ± 0.82

Adverse events

Collected over From the start of the study through to study completion (approx 1 year 11 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QR-110 Low Dose0/6 (0%)2/6 (33.3%)6/6 (100%)
QR-110 Mid Dose0/5 (0%)4/5 (80%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventQR-110 Low DoseQR-110 Mid Dose
CataractEye disorders2/64/5
Most frequent other events
Showing 10 of 24
Most frequent other events
EventQR-110 Low DoseQR-110 Mid Dose
Conjunctival haemorrhageEye disorders4/64/5
CataractEye disorders3/64/5
Lenticular opacitiesEye disorders1/63/5
Conjunctival hyperaemiaEye disorders1/62/5
Retinal degenerationEye disorders0/62/5
Anterior chamber cellEye disorders0/61/5
Conjunctival oedemaEye disorders0/61/5
Corneal lesionEye disorders0/61/5
Cystoid macular oedemaEye disorders0/61/5
DiplopiaEye disorders0/61/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)QR-110 Low DoseQR-110 Mid DoseTotal
Mean23.7 ± 15.0619.4 ± 6.8821.7 ± 11.71
Age, Customized
Age, Customized(Participants)QR-110 Low DoseQR-110 Mid DoseTotal
6 to < 18 years325
18 to < 65 years336
Sex: Female, Male
Sex: Female, Male(Participants)QR-110 Low DoseQR-110 Mid DoseTotal
Female246
Male415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)QR-110 Low DoseQR-110 Mid DoseTotal
Hispanic or Latino000
Not Hispanic or Latino6511
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)QR-110 Low DoseQR-110 Mid DoseTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6511
More than one race000
Unknown or Not Reported000
08

Study locations

3 sites
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Scheie Eye Institute, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Ghent University Hospital and Ghent University
    Ghent, B-9000, Belgium
09

References and documents

Publications

  • Russell SR, Drack AV, Cideciyan AV, Jacobson SG, Leroy BP, Van Cauwenbergh C, Ho AC, Dumitrescu AV, Han IC, Martin M, Pfeifer WL, Sohn EH, Walshire J, Garafalo AV, Krishnan AK, Powers CA, Sumaroka A, Roman AJ, Vanhonsebrouck E, Jones E, Nerinckx F, De Zaeytijd J, Collin RWJ, Hoyng C, Adamson P, Cheetham ME, Schwartz MR, den Hollander W, Asmus F, Platenburg G, Rodman D, Girach A. Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial. Nat Med. 2022 May;28(5):1014-1021. doi: 10.1038/s41591-022-01755-w. Epub 2022 Apr 4. PubMed 35379979 ↗
  • Cideciyan AV, Jacobson SG, Ho AC, Garafalo AV, Roman AJ, Sumaroka A, Krishnan AK, Swider M, Schwartz MR, Girach A. Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report. Nat Med. 2021 May;27(5):785-789. doi: 10.1038/s41591-021-01297-7. Epub 2021 Apr 1. PubMed 33795869 ↗
  • Miah KM, Hyde SC, Gill DR. Emerging gene therapies for cystic fibrosis. Expert Rev Respir Med. 2019 Aug;13(8):709-725. doi: 10.1080/17476348.2019.1634547. Epub 2019 Jun 27. PubMed 31215818 ↗
  • Cideciyan AV, Jacobson SG, Drack AV, Ho AC, Charng J, Garafalo AV, Roman AJ, Sumaroka A, Han IC, Hochstedler MD, Pfeifer WL, Sohn EH, Taiel M, Schwartz MR, Biasutto P, Wit W, Cheetham ME, Adamson P, Rodman DM, Platenburg G, Tome MD, Balikova I, Nerinckx F, Zaeytijd J, Van Cauwenbergh C, Leroy BP, Russell SR. Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect. Nat Med. 2019 Feb;25(2):225-228. doi: 10.1038/s41591-018-0295-0. Epub 2018 Dec 17. PubMed 30559420 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Oct 2019, 23 months.

Results were first posted in Dec 2022, 3 years 2 months after primary completion. A results delay was requested in Oct 2020.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2017
First posted
May 4, 2017
StartActual
Oct 16, 2017
Primary completionActual
Oct 2, 2019
CompletionActual
Oct 2, 2019
Results delay requested
Oct 1, 2020
Results first posted
Dec 27, 2022
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03140969
Lead sponsor
Laboratoires Thea
Collaborators
Sepul Bio
Responsible party
Sponsor
First posted
May 4, 2017
Start date
Oct 16, 2017
Primary completion
Oct 2, 2019
Completion
Oct 2, 2019
Results posted
Dec 27, 2022
Last update
Oct 15, 2024

Study contacts

Sepul Bio Chief Medical Officer
study director · Sepul Bio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sepofarsen

Start the discussion